194 related articles for article (PubMed ID: 2128973)
21. The differential glycosylation of human pro-urokinase from various recombinant mammalian cell lines does not affect activity and binding to PAI-1.
Sarubbi E; Nolli ML; Robbiati F; Soffientini A; Parenti F; Cassani G
Thromb Haemost; 1989 Nov; 62(3):927-33. PubMed ID: 2512681
[TBL] [Abstract][Full Text] [Related]
22. Fibrin-specific thrombolytic agents.
Collen D
Ann Biol Clin (Paris); 1988; 46(3):195-200. PubMed ID: 3044205
[TBL] [Abstract][Full Text] [Related]
23. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
Collen D; Stassen JM; Marafino BJ; Builder S; De Cock F; Ogez J; Tajiri D; Pennica D; Bennett WF; Salwa J
J Pharmacol Exp Ther; 1984 Oct; 231(1):146-52. PubMed ID: 6541693
[TBL] [Abstract][Full Text] [Related]
24. Synergism of thrombolytic agents in vivo.
Collen D; Stassen JM; Stump DC; Verstraete M
Circulation; 1986 Oct; 74(4):838-42. PubMed ID: 3093116
[TBL] [Abstract][Full Text] [Related]
25. [New thrombolytic agents].
Nguyen G; Samama M
Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
[TBL] [Abstract][Full Text] [Related]
26. Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass.
Spannagl M; Dooijewaard G; Dietrich W; Kluft C
Thromb Haemost; 1995 May; 73(5):825-8. PubMed ID: 7482410
[TBL] [Abstract][Full Text] [Related]
27. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments.
Gurewich V; Pannell R
Blood; 1987 Mar; 69(3):769-72. PubMed ID: 2949785
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
Vandamme AM; Dewerchin M; Lijnen HR; Bernar H; Bulens F; Nelles L; Collen D
Eur J Biochem; 1992 Apr; 205(1):139-46. PubMed ID: 1313361
[TBL] [Abstract][Full Text] [Related]
29. An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein.
Binnema DJ; Dooijewaard G; Turion PN
Thromb Haemost; 1991 Feb; 65(2):144-8. PubMed ID: 1905069
[TBL] [Abstract][Full Text] [Related]
30. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
J Biol Chem; 1988 Dec; 263(35):19083-91. PubMed ID: 3143723
[TBL] [Abstract][Full Text] [Related]
32. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
33. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
34. Differential detection of single-chain and two-chain urokinase-type plasminogen activator by a new immunoadsorbent-amidolytic assay (IAA).
Corti A; Nolli ML; Cassani G
Thromb Haemost; 1986 Dec; 56(3):407-10. PubMed ID: 3105110
[TBL] [Abstract][Full Text] [Related]
35. Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
Lijnen HR; Van Hoef B; Collen D
Eur J Biochem; 1987 Dec; 169(2):359-64. PubMed ID: 2961562
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of single chain forms of urokinase-type plasminogen activator.
Stump DC; Kieckens L; De Cock F; Collen D
J Pharmacol Exp Ther; 1987 Jul; 242(1):245-50. PubMed ID: 3612530
[TBL] [Abstract][Full Text] [Related]
37. In vitro effects of urokinase--prevention by different inhibitors.
Oethinger MD; Seifried E
Thromb Haemost; 1990 Nov; 64(3):402-6. PubMed ID: 1710833
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
Gurewich V; Pannell R; Broeze RJ; Mao J
J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
[TBL] [Abstract][Full Text] [Related]
39. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
40. A hybrid plasminogen activator binds to the u-PA receptor and has a reduced thrombolytic potency in vivo.
Asselbergs FA; Bürgi R; Hamerman J; Heim J; van Oostrum J; Agnelli G
Thromb Haemost; 1993 Jan; 69(1):50-5. PubMed ID: 8383359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
